Publications
By Year
Now showing items 4501-4520 of 5385 records
Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: the ADVANCE trial
Shaw, JE; Williams, B; Mancia, G; Cooper, ME; Chalmers, J; Sattar, N; Hamet, P; Woodward, M; Grobbee, DE; Jun, M; Rahimi, K; Welsh, P; Zoungas, S; Ohkuma, T
DIABETES CARE - 01 Sep 2017
OBJECTIVE: This study examined the individual and combined effect of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 (IL-6), and hs-CRP on the prediction of heart failure incidence or progression in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A nested case-cohort study was conducted in 3,098 participants ...
Cut points for identifying clinically significant diabetes distress in adolescents with type 1 diabetes using the PAID-T: results from diabetes MILES youth-Australia
Cameron, F; Hendrieckx, C; Pouwer, F; Skinner, TC; Hagger, V; Speight, J
DIABETES CARE - 01 Nov 2017
OBJECTIVE: To establish cut point(s) for the Problem Areas in Diabetes-teen version (PAID-T) scale to identify adolescents with clinically meaningful, elevated diabetes distress. RESEARCH DESIGN AND METHODS: Data were available from the Diabetes Management and Impact for Long-term Empowerment and Success (MILES) Youth-Australia Study, a national survey assessing various psychosocial indi...
Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities
Larsen, RN; Lambert, GW; Sacre, JW; Sethi, P; Dunstan, DW; Cerin, E; Dempsey, PC; Cohen, ND; Kingwell, BA; Owen, N; Straznicky, NE
DIABETES CARE - 01 Jun 2016
OBJECTIVE: To determine whether interrupting prolonged sitting with brief bouts of light-intensity walking (LW) or simple resistance activities (SRA) improves postprandial cardiometabolic risk markers in adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: In a randomized crossover trial, 24 inactive overweight/obese adults with T2D (14 men 62 ± 6 years old) underwent the foll...
Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON
Poulter, N; Neal, B; Matthews, D; Hamet, P; Williams, B; Harrap, S; Heller, S; ADVANCE-ON Collaborative Group; Wong, MG; Marre, M; Chalmers, J; Woodward, M; Rodgers, A; MacMahon, S; Li, Q; Perkovic, V; Mancia, G; Cooper, ME; Zoungas, S
DIABETES CARE - 01 May 2016
OBJECTIVE: The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes, but uncertainty about the balance between risks and benefits exists. Here, we examine the long-term effects of intensive glucose control on risk of ESKD and ot...
Age-specific trends from 2000-2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people
Shaw, JE; Davidson, S; Magliano, DJ; Peeters, A; Harding, JL
DIABETES CARE - 01 Jun 2016
OBJECTIVE: To analyze changes by age-group in all-cause and cause-specific mortality rates from 2000-2011 in people with diabetes. RESEARCH DESIGN AND METHODS: A total of 1,189,079 (7.3% with type 1 diabetes) Australians with diabetes registered on the National Diabetes Service Scheme between 2000 and 2011 were linked to the National Death Index. Mortality rates in the total population w...
Breaking up prolonged sitting with standing or walking attenuates the postprandial metabolic response in postmenopausal women: a randomized acute study
Gill, JM; Edwardson, CL; Stensel, DJ; Tolfrey, K; Khunti, K; Henson, J; Bodicoat, DH; Yates, T; Dunstan, DW; Davies, MJ
DIABETES CARE - 01 Jan 2016
OBJECTIVE: To determine whether breaking up prolonged sitting with short bouts of standing or walking improves postprandial markers of cardiometabolic health in women at high risk of type 2 diabetes. RESEARCH DESIGN AND METHODS: Twenty-two overweight/obese, dysglycemic, postmenopausal women (mean ± SD age 66.6 ± 4.7 years) each participated in two of the following treatments: prolonged, ...
Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes
Li, Q; Pickering, R; Chalmers, J; Cooper, ME; Williams, B; Perkovic, V; Woodward, M; Neal, B; Thomas, MC; ADVANCE Collaborative Group; Zoungas, S; Marre, M; Hillis, GS
DIABETES CARE - 01 Oct 2015
OBJECTIVE: This study explored whether activation of the receptor for advanced glycation end products (RAGE) is implicated in the development of diabetes complications. RESEARCH DESIGN AND METHODS: A case-cohort study was performed in 3,763 participants with prevalent diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (A...
The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes
Masar, R; Harjutsalo, V; Thorn, LM; Saraheimo, M; Wadén, J; Hägg, S; Forsblom, CM; Groop, PH; Tolonen, N; Gordin, D; FinnDiane Study Group
DIABETES CARE - 01 Nov 2015
OBJECTIVE: This study investigated the prevalence of nonalbuminuric chronic kidney disease in type 1 diabetes to assess whether it increases the risk of cardiovascular and renal outcomes as well as all-cause mortality. RESEARCH DESIGN AND METHODS: This was an observational follow-up of 3,809 patients with type 1 diabetes from the Finnish Diabetic Nephropathy Study. All patients were Cauc...
Determinants of diabetes remission and glycemic control after bariatric surgery
Sjöström, L; Mingrone, G; Carlsson, L; Panunzi, S; Peltonen, M; De Gaetano, A; Rice, T; Dixon, JB
DIABETES CARE - 01 Jan 2016
OBJECTIVE: Eligibility criteria for bariatric surgery in diabetes include BMI ≥35 kg/m(2) and poorly controlled glycemia. However, BMI does not predict diabetes remission, and thus, predictors need to be identified. RESEARCH DESIGN AND METHODS: Seven hundred twenty-seven patients were included in a database merged from the Swedish Obese Subjects (SOS) study and two randomized controlled ...
Excess risk of dying from infectious causes in those with type 1 and type 2 diabetes
Shaw, JE; Magliano, DJ; Cohen, K; Davis, WA; Huxley, RR; Harding, JL
DIABETES CARE - 01 Jul 2015
OBJECTIVE: To investigate infection-related mortality in individuals with type 1 and type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 1,108,982 individuals with diabetes who were registered with the Australian Diabetes register between 2000 and 2010 were linked to the National Death Index. Mortality outcomes were defined as infection-related(A-B) death (ICD codes A99-B99), pneumonia ...
Kidney injury molecule-1 and the loss of kidney function in diabetic nephropathy: a likely causal link in patients with type 1 diabetes
Sandholm, N; Harjutsalo, V; Thorn, LM; Saraheimo, M; Wadén, J; Bierhaus, A; Forsblom, C; Humpert, PM; Groop, PH; Panduru, NM; Tolonen, N; Gordin, D; Dahlström, EH; FinnDiane Study Group
DIABETES CARE - 01 Jun 2015
OBJECTIVE: We evaluated the predictive value and clinical benefit of urinary kidney injury molecule (KIM)-1 for progression of diabetic nephropathy (DN) in type 1 diabetes. We also investigated its causal role for the decrease of estimated glomerular filtration rate (eGFR) by a Mendelian randomization (MR) approach. RESEARCH DESIGN AND METHODS: We followed 1,573 patients with type 1 diab...
Urinary adiponectin is an independent predictor of progression to end-stage renal disease in patients with type 1 diabetes and diabetic nephropathy
Thorn, LM; Saraheimo, M; Wadén, J; Bierhaus, A; Forsblom, C; Groop, PH; Humpert, PM; Panduru, NM; Tolonen, N; Gordin, D; FinnDiane Study Group
DIABETES CARE - 01 May 2015
OBJECTIVE: We investigated the predictive value of urinary adiponectin (uADP) for the progression of diabetic nephropathy (DN) as well as for the principal determinants of uADP concentrations. RESEARCH DESIGN AND METHODS: uADP was measured in 2,090 patients with type 1 diabetes followed for a median of 5.8 (4.4-6.9) years and in 111 subjects without diabetes. Progression was defined as a...
Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation
Shaw, JE; Magliano, DJ; Peeters, A; Cartensen, B; Harding, JL
DIABETES CARE - 01 Feb 2015
OBJECTIVE: Evidence indicates an increased risk of certain cancers among people with type 2 diabetes. Evidence for rarer cancers and for type 1 diabetes is limited. We explored the excess risk of site-specific cancer incidence and mortality among people with type 1 and type 2 diabetes, compared with the general Australian population. RESEARCH DESIGN AND METHODS: Registrants of a national dia...
Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes
Ilonen, J; Ryhänen, SJ; Salonen, KM; Knip, M; Simell, O; Veijola, R; Härkönen, T; Groop, PH; Forbes, JM; Borg, DJ
DIABETES CARE - 01 Apr 2015
OBJECTIVE: Dietary advanced glycation end products (AGEs) and their interactions with the receptor for AGEs (RAGE) may play a role in the pathogenesis of type 1 diabetes. This study set out to assess whether there is any association of circulating concentrations of soluble RAGE (sRAGE), AGEs, and their ratio with the appearance of diabetes-associated autoantibodies in children progressing to...
Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study
Sanders, KM; Walder, K; Orford, N; Phillips, G; Krippner, G; Nicholson, GC; MacGinley, R; Skoff, K; Wacher, VJ; Sarah, A; Simpson, RW; Chambers, J; Proietto, J
DIABETES CARE - 01 Nov 2014
OBJECTIVE: To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes. RESEARCH DESIGN AND METHODS: This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point for methazolamide treatment was a placebo-corrected reduction in HbA1c from baseline after 24 wee...
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial
Poulter, N; Harrap, S; Chalmers, J; Mancia, G; Hirakawa, Y; Ninomiya, T; Hamet, P; Woodward, M; Cooper, M; Zoungas, S; Arima, H
DIABETES CARE - 01 Aug 2014
OBJECTIVE: There is no consensus on the importance of visit-to-visit glycemic variability in diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA1c and fasting glucose on major outcomes in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial. RESEARCH DESIGN AND METHODS: ADVANCE was a factorial randomi...
Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes
Sandholm, N; Soro-Paavonen, A; Harjutsalo, V; Bjerre, M; Forsblom, C; Groop, PH; Thomas, MC; Flyvbjerg, A; Panduru, NM; Tolonen, N; Gordin, D; FinnDiane Study Group
DIABETES CARE - 01 Sep 2014
OBJECTIVE: Osteopontin (OPN) is a multifunctional protein suggested to be a player in the arterial disease of patients with type 2 diabetes. However, its role for complications in patients with type 1 diabetes (T1D) is unknown. We therefore investigated the associations between OPN and diabetic vascular complications and all-cause mortality in patients with T1D. RESEARCH DESIGN AND METHODS: Se...
Circulating concentrations of soluble receptor for AGE are associated with age and AGER gene polymorphisms in children with newly diagnosed type 1 diabetes
Laine, AP; Ryhänen, SJ; Ilonen, J; Finnish Pediatric Diabetes Register; Salonen, KM; Knip, M; Forbes, JM; Härkönen, T; Groop, PH
DIABETES CARE - 01 Jul 2014
OBJECTIVE: We analyzed the relationship among soluble receptor for advanced glycation end products (sRAGEs), the clinical phenotype, HLA genotype, and risk-associated single nucleotide polymorphisms (SNPs) in the AGER gene in a large population of Finnish children with newly diagnosed type 1 diabetes. RESEARCH DESIGN AND METHODS: Samples from 2,115 clinically phenotyped children <15 year...
Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: the FinnDiane study
Sandholm, N; Mäkinen, VP; Feodoroff, M; Harjutsalo, V; Thorn, LM; Wadén, J; Forsblom, C; Groop, PH; Taskinen, MR; Tolonen, N; Gordin, D; FinnDiane Study Group
DIABETES CARE - 01 Aug 2014
OBJECTIVE: To study the ability of lipid variables to predict incident coronary artery disease (CAD) events in patients with type 1 diabetes at different stages of nephropathy. RESEARCH DESIGN AND METHODS: Patients (n = 3,520) with type 1 diabetes and available lipid profiles participating in the Finnish Diabetic Nephropathy Study (FinnDiane) were included in the study. During a follow-u...
Living well with diabetes: 24-month outcomes from a randomized trial of telephone-delivered weight loss and physical activity intervention to improve glycemic control
Winkler, EA; Dunstan, DW; Reeves, MM; Healy, GN; Graves, N; Eakin, EG; Marshall, AM; Owen, N
DIABETES CARE - 01 Aug 2014
OBJECTIVE: To evaluate the effectiveness of a telephone-delivered behavioral weight loss and physical activity intervention targeting Australian primary care patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Pragmatic randomized controlled trial of telephone counseling (n = 151) versus usual care (n = 151). Reported here are 18-month (end-of-intervention) and 24-month (maintenance) p...
Show more...